Implantable Septal Shunt Improves Cardiac Function
By HospiMedica International staff writers Posted on 11 Jan 2021 |
Image: The Occlutech implantable atrial flow regulator (AFR) (Photo courtesy of Occlutech)
An implantable atrial flow regulator (AFR) substantially reduces intra-cardiac pressure resulting from pulmonary arterial hypertension (PAH).
The Occlutech (Schaffhausen, Switzerland) AFR is a nickel-titanium (nitinol) shunt placed into the septum between the left and right atriums via balloon atrial septostomy (BAS), in order to create a permanent interatrial fenestration. By selecting and maintaining correct sizing of the created shunt (between six and 10 mm), the AFR allows for a controlled, restricted flow of blood between the atria, thus reducing intra-cardiac pressure and improving the heart's function.
The AFD is intended for heart failure patients with a preserved ejection fraction (HFpEF) that includes diminished left ventricle relaxation and elevated filling pressures. By creating a communication between both atria using BAS, decompression of the left atrium is achieved. The design of the device was based on the concept of the Lutembacher syndrome, a medical condition defined as a combination of mitral stenosis and atrial septal defect (ASD).
PAH is a rare, progressive disorder characterized by high blood pressure in the pulmonary artery for no apparent reason. Symptoms of PAH include shortness of breath (dyspnea) especially during exercise, chest pain, and fainting episodes. Advanced stages of PAH may manifest in cyanosis due to low levels of circulating oxygen. In severe cases of PAH, the right ventricle is abnormally enlarged, potentially leading to right heart failure.
Related Links:
Occlutech
The Occlutech (Schaffhausen, Switzerland) AFR is a nickel-titanium (nitinol) shunt placed into the septum between the left and right atriums via balloon atrial septostomy (BAS), in order to create a permanent interatrial fenestration. By selecting and maintaining correct sizing of the created shunt (between six and 10 mm), the AFR allows for a controlled, restricted flow of blood between the atria, thus reducing intra-cardiac pressure and improving the heart's function.
The AFD is intended for heart failure patients with a preserved ejection fraction (HFpEF) that includes diminished left ventricle relaxation and elevated filling pressures. By creating a communication between both atria using BAS, decompression of the left atrium is achieved. The design of the device was based on the concept of the Lutembacher syndrome, a medical condition defined as a combination of mitral stenosis and atrial septal defect (ASD).
PAH is a rare, progressive disorder characterized by high blood pressure in the pulmonary artery for no apparent reason. Symptoms of PAH include shortness of breath (dyspnea) especially during exercise, chest pain, and fainting episodes. Advanced stages of PAH may manifest in cyanosis due to low levels of circulating oxygen. In severe cases of PAH, the right ventricle is abnormally enlarged, potentially leading to right heart failure.
Related Links:
Occlutech
Latest Critical Care News
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration